Chronic Migraine and Medication Overuse Headache

Chronic Migraine and Medication Overuse — scientific infographic poster

Table of Contents

  1. Episodic vs Chronic — The ICHD-3 Definitions
  2. How Episodic Becomes Chronic
  3. Medication Overuse Headache — The Thresholds
  4. Why Opioids and Butalbital Are the Worst Offenders
  5. What MOH Does to the Brain
  6. Withdrawal — Cold Turkey vs Taper
  7. Bridge Therapy During Detox
  8. Inpatient vs Outpatient Detox
  9. OnabotulinumtoxinA — The PREEMPT Protocol
  10. CGRP Antibodies for Chronic Migraine
  11. Neuromodulation Devices
  12. Nerve Blocks
  13. Lifestyle Stabilization as Foundation
  14. Tracking: Diaries and Apps
  15. What Recovery Looks Like
  16. Disability Claims in Chronic Migraine
  17. Key Research Papers
  18. Connections
  19. Featured Videos

Episodic vs Chronic — The ICHD-3 Definitions

The International Classification of Headache Disorders, third edition (ICHD-3) — the rulebook neurologists use — draws a sharp line between episodic and chronic migraine. The line is drawn at 15 headache days per month.

Those "8 migraine days" matter. Many people with chronic migraine have a mix — some days the headache is a full migraine attack with nausea, light sensitivity, and throbbing unilateral pain; other days it is a lower-grade "tension-type" ache that still keeps them from functioning. ICHD-3 counts all of those days toward the 15, as long as at least 8 have migraine features.

The diagnostic label matters because it unlocks treatments. OnabotulinumtoxinA, for example, is U.S. Food and Drug Administration-approved only for chronic migraine — not for episodic. Many insurers demand documented chronic migraine (15+ days/month) before paying for CGRP injections, onabotulinumtoxinA, or neuromodulation devices. The diary you keep at home is the evidence that gets you access to the treatment you need.

How Episodic Becomes Chronic

Roughly 2.5% of episodic migraine patients progress to chronic migraine every year — a finding from the American Migraine Prevalence and Prevention (AMPP) study led by Marcelo Bigal and Richard Lipton. That is not a huge absolute number, but across a long disease course it adds up: someone with migraine since their twenties has a meaningful probability of crossing into chronic territory by midlife if risk factors stack.

The strongest modifiable risk factors for chronification:

The good news, buried in the same epidemiology: patients can "re-convert" from chronic back to episodic. Anywhere from 45% to 70% of chronic migraine sufferers who also overuse analgesics will drop below 15 headache days per month within two to six months of detox. Randomized trials have since tested how much the withdrawal itself adds. In a Danish trial of 120 people, reversion to episodic headache at 6 months was 74.2% with withdrawal plus a preventive, 60.0% with a preventive without withdrawal, and 41.7% with withdrawal alone (P=.03). In the MOTS trial of 720 people, a preventive without switching or limiting the overused drug was not inferior to a preventive with switching (9.1 vs 9.3 moderate to severe headache days over 4 weeks).

Medication Overuse Headache — The Thresholds

Medication overuse headache (MOH) is a specific ICHD-3 diagnosis in its own right. It is defined as headache on 15 or more days per month in a person with a pre-existing headache disorder, caused by regular overuse of acute or symptomatic headache medication for more than 3 months. The thresholds:

Two traps catch most patients. First, these thresholds are per month, every month, for three months. A bad week does not cause MOH — a bad pattern does. Second, people routinely underestimate their use because they grab "just one" on dozens of workdays. A headache diary tends to reveal usage double what the patient quoted from memory.

The gepants — ubrogepant, rimegepant — appear to not cause MOH in the same way, and rimegepant is actually approved for both acute and preventive use. This is one of the most clinically important differences between the triptan era and the gepant era, and it is why neurologists increasingly steer patients with frequent attacks toward gepants.

Why Opioids and Butalbital Are the Worst Offenders

All acute migraine medications can cause MOH if overused, but they are not equally bad. The risk hierarchy, from worst to least bad:

  1. Opioids. Cause MOH faster than any other class and, with barbiturates, are associated with the highest rate of progression from episodic to chronic migraine. Opioids also sensitize pain pathways systemically, worsen sleep, and offer minimal benefit for most migraine attacks. No current migraine guideline recommends opioids for routine migraine care.
  2. Butalbital combinations. Butalbital is a barbiturate with addiction potential, strong rebound, and nasty withdrawal (anxiety, insomnia, seizures at high doses). The AMPP data found a dose-response relationship between barbiturate use and progression to chronic migraine.
  3. Combination analgesics with caffeine. Caffeine is itself a headache driver in overuse. Many MOH cases are driven by a daily caffeine-containing pill plus daily coffee.
  4. Triptans. Effective drugs that cause MOH at a well-defined threshold (10 days/month). Most patients do fine staying under the limit.
  5. Plain nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. Cause MOH too, but the threshold is higher (15 days/month), and they are the safest of the commonly used classes from an MOH standpoint.

For people on daily opioids or butalbital for migraine, the concern raised by this research is about physiology, not blame or addiction stigma. These drugs make the underlying brain disorder worse the longer they are used.

What MOH Does to the Brain

In plain language: the brain adapts to whatever you feed it daily. Feed it triptans every day and the serotonin receptors those drugs target downregulate — there are fewer of them, and they respond less vigorously. Feed it opioids every day and the mu-opioid system rewires, amplifying pain input instead of dampening it (opioid-induced hyperalgesia). Feed it caffeine-containing combination pills every day and caffeine withdrawal headaches start between doses.

Underneath all of this sits the trigeminovascular system — the nerve network that carries migraine pain from meningeal blood vessels through the trigeminal nerve into the brainstem and up into the thalamus. In MOH, this system becomes hyper-responsive. Animal studies show that repeated triptan or opioid exposure produces central sensitization: the threshold for triggering a headache drops, and normal stimuli (a skipped meal, a noisy room, a weather front) that would once have passed without incident now reliably set off attacks.

The upshot is that you cannot reason or willpower your way out of MOH. The brain has been rewired by the medication, and stopping the medication lets the system normalize. That takes weeks, not days, and feels awful in the middle. Trials differ on whether stopping has to come first: the MOTS trial above found that a preventive without limiting the overused drug was not inferior, and the Danish trial found withdrawal plus a preventive gave the highest reversion.

Withdrawal — Cold Turkey vs Taper

"Detox" in headache medicine means stopping the overused acute medication. There are two approaches, and your class of drug dictates which is safe.

Cold turkey is standard for triptans, ergots, nonsteroidal anti-inflammatory drugs, acetaminophen, and combination analgesics. The person picks a start date and stops on that date. The first 2 weeks are typically the worst — headache intensifies, nausea worsens, sleep suffers. By week 3 or 4, most patients begin to see daylight. By week 8, headache days have usually dropped substantially.

Structured taper is mandatory for opioids (physiologic dependence, autonomic withdrawal) and butalbital (risk of seizures if stopped abruptly after long-term high-dose use). A typical butalbital taper cuts the dose by 10–25% every one to two weeks under physician supervision. Opioid tapers follow the same slow principle and sometimes benefit from adjunct clonidine or buprenorphine bridging.

The rebound period — the stretch where headaches worsen before they improve — generally runs 2 to 8 weeks. Most patients who will benefit from detox see their headache days drop by week 8. Some take up to 12 weeks. The worst part is time-limited.

A 6-month Danish trial compared three strategies in 120 people. Headache days per month fell by 12.3 with withdrawal plus a preventive, 9.9 with a preventive alone, and 8.5 with withdrawal alone (P=.20, not a significant difference). Medication overuse headache was cured in 96.8%, 74.3% and 88.9% respectively.

Bridge Therapy During Detox

"Bridge therapy" means short-term treatments used only during the detox window to blunt the rebound. These are not daily forever-medications — they are training wheels that come off after 1–4 weeks. Common options:

What is not known: how much any bridge adds. The corticosteroid trials above found no advantage over placebo. Raskin’s original 1986 report gave IV DHE plus metoclopramide to 55 patients: 49 became headache-free within 48 hours and 39 kept the benefit at a mean of 16 months. Its comparator was intravenous diazepam, not placebo (7 of 54 headache-free within 3 to 6 days).

Starting a preventive at the same time as detox is standard practice — topiramate, a beta-blocker, amitriptyline, a CGRP antibody, or onabotulinumtoxinA all work better once the brain is no longer being overwhelmed by the overused medication.

Inpatient vs Outpatient Detox

Most MOH detox happens outpatient. A typical outpatient plan: stop the overused drug on day zero, start a preventive, run a bridge (often scheduled naproxen plus a prednisone taper), and schedule follow-up at 2, 4, and 8 weeks. This works for the majority.

Inpatient detox — usually a 3 to 5 day admission to a headache specialty unit — is reserved for:

A handful of U.S. centers run dedicated inpatient headache programs. Insurance coverage varies and often requires prior authorization with documentation of failed outpatient attempts.

OnabotulinumtoxinA — The PREEMPT Protocol

OnabotulinumtoxinA was U.S. Food and Drug Administration-approved for chronic migraine in 2010 on the strength of the two PREEMPT trials. The protocol is precise.

The two PREEMPT trials (Aurora 2010, Diener 2010) each enrolled around 700 chronic migraine patients. The size of the effect shows when the placebo arm is set beside it. PREEMPT 1 missed its primary endpoint, headache episodes (−5.2 vs −5.3 with placebo, p=0.344), though headache days and migraine days differed significantly. PREEMPT 2 met its primary endpoint, headache days (−9.0 vs −6.7). Pooled, the two trials gave 8.4 fewer headache days against 6.6 fewer with placebo at 24 weeks (P<.001). Adverse events occurred in 62.4% vs 51.7%. Clinicians often describe full response as taking two or three cycles.

Practical points. OnabotulinumtoxinA for migraine is delivered by someone trained in the PREEMPT protocol — most often a headache-specialist neurologist, not a cosmetic injector. Insurance typically requires documented chronic migraine (15+ days/month) plus failure of two or three oral preventives. The injections take about 15 minutes and feel like a series of bee stings. Mild neck soreness is common for a day or two. Eyelid or eyebrow droop is rare when the protocol is followed correctly.

CGRP Antibodies for Chronic Migraine

All four monoclonal antibodies targeting the calcitonin-gene-related peptide (CGRP) pathway are approved for chronic migraine. They are the first preventive class developed specifically for migraine rather than borrowed from other specialties.

Expected benefit in chronic migraine trials: about 4 to 7 fewer migraine days per month, with 30–40% of patients achieving 50% or better reduction. Placebo also lowers the count: in a phase 2 trial of 667 people, erenumab cut 6.6 migraine days a month against 4.2 with placebo (difference 2.5). Side-effect profile is remarkably clean — injection-site reactions, constipation (particularly with erenumab), and occasional blood pressure elevation are the main concerns. Unlike topiramate, they do not cause cognitive fog or weight loss. Unlike amitriptyline, they do not cause sedation. Unlike onabotulinumtoxinA, they work on their own schedule without 31 needles every 12 weeks. See the CGRP inhibitors deep-dive for the full comparison.

Importantly, CGRP antibodies work even in the presence of ongoing medication overuse — trial data and real-world cohorts show benefit before full detox is achieved. This has changed practice: many clinicians now start a CGRP monoclonal on day zero of detox, making the rebound period more bearable and improving the odds of success.

Daily tablets now exist too. In the PROGRESS trial (778 randomized, about 19 migraine days a month at the start), atogepant cut 7.5 days at 30 mg twice daily and 6.9 days at 60 mg once daily, against 5.1 with placebo over 12 weeks. Constipation and nausea were the most common side effects.

First-line status. In 2024 the American Headache Society stated that CGRP-targeting treatments should be considered a first-line approach “without a requirement for prior failure of other classes of migraine preventive treatment.”

Neuromodulation Devices

Four wearable devices are U.S. Food and Drug Administration-cleared for migraine, and all can be useful in chronic migraine and MOH where drug options are limited or maxed out:

Effect sizes are modest compared with onabotulinumtoxinA or CGRP antibodies, but the devices have almost no systemic side effects, which makes them particularly attractive for patients who cannot tolerate medications, who are pregnant, or who are in the middle of MOH detox and want a non-drug option to reach for instead of another pill.

Nerve Blocks

Two office-based nerve-block procedures are standard in chronic migraine:

Both are typically covered by insurance when performed by a headache specialist or pain physician, and both act locally rather than through the whole body, for patients who cannot take more systemic medication.

Lifestyle Stabilization as Foundation

Every patient hates the "sleep, eat, hydrate, exercise" lecture, and every headache specialist gives it anyway because it works. In chronic migraine, the brain is already hypersensitive. Variation in sleep, meals, caffeine, or stress lands harder than it would on an episodic brain. The foundation clinics describe:

See the diet triggers article and the supplement protocol for the detailed nutrition and supplement piece.

Tracking: Diaries and Apps

You cannot manage what you do not measure, and insurance companies will not pay for advanced treatments without documented headache days. A good diary captures, for each day: headache yes/no, severity 0–10, duration, any medication taken (dose and time), menstrual day, sleep hours, and suspected triggers. Useful tools:

A printed or exported report gives exact counts. "About two weeks a month, I think" is a losing argument with insurance. "18 headache days in March, 16 in April, 17 in May" is a winning one.

What Recovery Looks Like

Recovery from chronic migraine with MOH is measured in weeks to months, not days. A realistic timeline for someone doing outpatient detox plus a new preventive:

Re-converting from chronic to episodic is a real, studied outcome. It does not happen for everyone — roughly half to two-thirds of motivated patients who complete detox and maintain a preventive end up back in the episodic range. The other third may remain chronic but with fewer overall headache days and better function. Either is a meaningful win.

Sleep often recovers too. Among 171 people with medication overuse headache, chronic insomnia was 60.2% and restless legs 37.4%, falling to 33.3% and 14.9% after headache treatment (mean follow-up about 2 years in 87 patients).

Clinicians describe relapse as a common risk: the brain has a long memory, and reintroducing daily triptans, daily caffeine-containing combination pills, or daily opioids is described as dragging patients back into chronic territory within months. Acute medication is meant for acute attacks, and some clinicians set a line at 8 days of acute use per month, not 10, as a safety margin.

Disability Claims in Chronic Migraine

Not every person with chronic migraine can keep working full time, and that is nothing to be ashamed of. Signs commonly cited in disability claims:

The U.S. Social Security Administration does not have a dedicated migraine listing, but chronic migraine can qualify under listings for neurological impairment (11.00 series) or, more often, via a medical-vocational allowance that adds up headache days, cognitive limitations, and documented treatment failures. Private long-term disability (LTD) policies through employers are often more accessible than SSDI; what such a policy pays depends on its definition of "own occupation" vs "any occupation." Detailed headache diaries, neurologist letters, onabotulinumtoxinA and CGRP records, and work absence documentation are the paper trail that wins these claims. Specialized disability attorneys handle contested cases, with a 25% contingency fee commonly quoted.

Key Research Papers

  1. Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. — doi:10.1177/0333102410364676
  2. Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814. — doi:10.1177/0333102410364677
  3. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol. 2007;20(3):326–330. — doi:10.1097/wco.0b013e328136c21c
  4. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008. — doi:10.1111/j.1526-4610.2007.00969.x
  5. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936. — PubMed PMID: 20487038
  6. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–1168. — PubMed PMID: 18808500
  7. Carlsen LN, Munksgaard SB, Nielsen M, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 2020;77(9):1069–1078. — PubMed PMID: 32453406
  8. Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology. 2022;98(14):e1409–e1421. — PubMed PMID: 35169011
  9. Bøe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology. 2007;69(1):26–31. — PubMed PMID: 17475943
  10. Rabe K, Pageler L, Gaul C, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33(3):202–207. — PubMed PMID: 23093541
  11. da Silva EG, de Sousa JR, Moraes Monteiro Barbosa Barros M, de Oliveira FAA, Rocha-Filho PAS. Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review. Expert Rev Neurother. 2026;26(8):795–804. — PubMed PMID: 42332418
  12. Lee MJ, Park HK, Oh SY, et al. Effect of prednisolone for the treatment of medication-overuse headache: a 3-month result from a multicenter REgistry for Load and management of mEdicAtion overuSE headache (RELEASE) study. Headache. 2024;64(2):149–155. — PubMed PMID: 38284247
  13. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995–997. — PubMed PMID: 3520384
  14. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. — PubMed PMID: 28460892
  15. Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775–785. — PubMed PMID: 37516125
  16. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333–341. — PubMed PMID: 38466028
  17. Lebedeva ER, Kniazeva IA, Gilev DV, Olesen J. Sleep disorders in medication-overuse headache: prevalence and associated factors. Eur J Neurol. 2026;33(7):e70685. — PubMed PMID: 42460796

PubMed Topic Searches

For further reading, these PubMed topic searches return current peer-reviewed work on chronic migraine and medication overuse headache:

  1. PubMed: Chronic migraine ICHD-3 criteria
  2. PubMed: Medication overuse headache detox strategies
  3. PubMed: OnabotulinumtoxinA PREEMPT protocol
  4. PubMed: CGRP monoclonal antibodies in chronic migraine
  5. PubMed: Opioid and butalbital overuse headache
  6. PubMed: Episodic to chronic migraine chronification
  7. PubMed: Occipital nerve blocks for migraine
  8. PubMed: Neuromodulation devices for migraine

Back to Table of Contents

Connections

Back to Table of Contents